Advancements in CLL Treatment

This chapter explores recent research findings on chronic lymphocytic leukemia (CLL) treatments, focusing on the efficacy of second and third-generation BTK inhibitors like acalabrutinib and zanabrutinib. The discussion highlights the importance of cardiovascular assessments and careful management of bleeding risks, particularly in elderly and frail patients undergoing therapy.